Inhibition of Hsp110-STAT3 interaction in endothelial cells alleviates vascular remodeling in hypoxic pulmonary arterial Hypertension model

[1]  Qinglian Liu,et al.  A first-in-class inhibitor of Hsp110 molecular chaperones of pathogenic fungi , 2023, Nature communications.

[2]  Qianbin Li,et al.  Pulmonary artery smooth muscle cell phenotypic switching: A key event in the early stage of pulmonary artery hypertension. , 2023, Drug discovery today.

[3]  D. Pascual,et al.  Comentarios a la guía ESC/ERS 2022 sobre el diagnóstico y tratamiento de la hipertensión pulmonar , 2023, Revista Española de Cardiología.

[4]  C. Garrido,et al.  Discovery of second generation heat shock protein 110 (HSP110) inhibitors for potential treatment of colorectal cancer , 2023, European Journal of Medicinal Chemistry Reports.

[5]  D. Pascual,et al.  Comments to the 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. , 2022, Revista espanola de cardiologia.

[6]  Wei Chen,et al.  Knockdown of HSP110 attenuates hypoxia-induced pulmonary hypertension in mice through suppression of YAP/TAZ-TEAD4 pathway , 2022, Respiratory Research.

[7]  Qianbin Li,et al.  TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats. , 2022, Vascular pharmacology.

[8]  Kun Sun,et al.  Caspase-4/11–Mediated Pulmonary Artery Endothelial Cell Pyroptosis Contributes to Pulmonary Arterial Hypertension , 2022, Hypertension.

[9]  Qianbin Li,et al.  An emerging strategy for targeted therapy of pulmonary arterial hypertension: vasodilation plus vascular remodeling inhibition. , 2022, Drug discovery today.

[10]  L. Farkas,et al.  Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension , 2021, International journal of molecular sciences.

[11]  Lijun Li,et al.  Novel Pyrazolo[3,4-b] Pyridine Derivative (HLQ2g) Attenuates Hypoxic Pulmonary Hypertension via Restoring cGKI Expression and BMP Signaling Pathway , 2021, Frontiers in Pharmacology.

[12]  Qinglian Liu,et al.  Interdomain interactions dictate the function of the Candida albicans Hsp110 protein Msi3 , 2021, The Journal of biological chemistry.

[13]  Qinglian Liu,et al.  Purification and biochemical characterization of Msi3, an essential Hsp110 molecular chaperone in Candida albicans , 2021, Cell Stress and Chaperones.

[14]  Lei Wang,et al.  Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer , 2021, Medicinal research reviews.

[15]  Xiangrui Jiang,et al.  Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. , 2020, Journal of medicinal chemistry.

[16]  J. Ryan,et al.  Management of Pulmonary Arterial Hypertension , 2020, Current Cardiovascular Risk Reports.

[17]  Qinglian Liu,et al.  Discovery of Novel Pyrazolo[3,4-b] pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension. , 2020, Journal of medicinal chemistry.

[18]  Qianbin Li,et al.  Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin. , 2020, Journal of medicinal chemistry.

[19]  Li Li,et al.  Heat shock protein 90 (Hsp90) Inhibitors: An Update on Achievements, Challenges, and Future Directions. , 2020, Journal of medicinal chemistry.

[20]  S. Rosenkranz,et al.  Current and future treatments of pulmonary arterial hypertension , 2020, British journal of pharmacology.

[21]  Lei Wang,et al.  Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery , 2020, Acta pharmaceutica Sinica. B.

[22]  C. Garrido,et al.  Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy , 2019, Cancers.

[23]  R. Rafikov,et al.  Focus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development , 2019, Antioxidants & redox signaling.

[24]  Yanqing Ding,et al.  KNK437 restricts the growth and metastasis of colorectal cancer via targeting DNAJA1/CDC45 axis , 2019, Oncogene.

[25]  Jian Zhang,et al.  Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer , 2019, Science Advances.

[26]  D. Mould,et al.  Pharmacokinetic and Pharmacodynamic Effects of Oral CXA‐10, a Nitro Fatty Acid, After Single and Multiple Ascending Doses in Healthy and Obese Subjects , 2019, Clinical and translational science.

[27]  O. Demidov,et al.  Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy , 2019, Cell Death & Differentiation.

[28]  I. Rahman,et al.  Association of smoking and electronic cigarette use with wheezing and related respiratory symptoms in adults: cross-sectional results from the Population Assessment of Tobacco and Health (PATH) study, wave 2 , 2019, Tobacco Control.

[29]  J. Wang,et al.  HMGB1/TLR4 promotes hypoxic pulmonary hypertension via suppressing BMPR2 signaling. , 2019, Vascular pharmacology.

[30]  Paul G. Williams,et al.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.

[31]  D. Altieri,et al.  Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension , 2018, American journal of respiratory and critical care medicine.

[32]  S. Archer,et al.  Pulmonary arterial hypertension: pathogenesis and clinical management , 2018, British Medical Journal.

[33]  O. Demidov,et al.  HSP110 promotes colorectal cancer growth through STAT3 activation , 2017, Oncogene.

[34]  H. Palevsky,et al.  Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double‐Blind, Placebo‐controlled Trial , 2016, American journal of respiratory and critical care medicine.

[35]  W. Seeger,et al.  Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension , 2016, European Respiratory Journal.

[36]  M. Gladwin,et al.  Strategies to increase nitric oxide signalling in cardiovascular disease , 2015, Nature Reviews Drug Discovery.

[37]  C. Tripodo,et al.  HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. , 2015, Blood.

[38]  Yibing Yan,et al.  HSP105 Recruits Protein Phosphatase 2A To Dephosphorylate β-Catenin , 2015, Molecular and Cellular Biology.

[39]  M. Humbert,et al.  Pathogenesis of pulmonary arterial hypertension: lessons from cancer , 2013, European Respiratory Review.

[40]  M. Humbert,et al.  Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.

[41]  Andrija Finka,et al.  Hsp110 Is a Bona Fide Chaperone Using ATP to Unfold Stable Misfolded Polypeptides and Reciprocally Collaborate with Hsp70 to Solubilize Protein Aggregates* , 2013, The Journal of Biological Chemistry.

[42]  Nadinath B. Nillegoda,et al.  Metazoan Hsp70 machines use Hsp110 to power protein disaggregation , 2012, The EMBO journal.

[43]  C. Tournigand,et al.  Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis , 2011, Nature Medicine.

[44]  H. Ghofrani,et al.  Mechanisms of disease: pulmonary arterial hypertension , 2011, Nature Reviews Cardiology.

[45]  S. Erzurum,et al.  Endothelial cell energy metabolism, proliferation, and apoptosis in pulmonary hypertension. , 2010, Comprehensive Physiology.

[46]  J. Pelletier,et al.  Target identification using drug affinity responsive target stability (DARTS) , 2009, Proceedings of the National Academy of Sciences.

[47]  J. Michálek,et al.  Significant overexpression of Hsp110 gene during colorectal cancer progression. , 2009, Oncology reports.

[48]  M. Hoeper,et al.  Endothelin receptor antagonists in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[49]  R. Barst,et al.  Prostanoid therapy for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[50]  D. Easton,et al.  The Chaperoning Activity of hsp110 , 1999, The Journal of Biological Chemistry.

[51]  Chunhua Zhang,et al.  Drug Affinity Responsive Target Stability (DARTS ) Assay to Detect Interaction Between a Purified Protein and a Small Molecule. , 2021, Methods in molecular biology.